A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).
Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have:
All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.
Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Phase 1b Inclusion Criteria:
Phase 1b Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Birmingham, Alabama 35249, United States
Los Angeles, California 90025, United States
Los Angeles, California 90033, United States
San Francisco, California 94143, United States
San Francisco, California 94143, United States
San Francisco, California 94158, United States
Santa Monica, California 90404, United States
Tampa, Florida 33612, United States
Saint Louis Park, Minnesota 55426, United States
Saint Louis Park, Minnesota 55426, United States
Saint Paul, Minnesota 55101, United States
New York, New York 10016, United States
New York, New York 10022, United States
New York, New York 10032, United States
New York, New York 10065, United States
Cleveland, Ohio 44106, United States
Madison, Wisconsin 53718, United States
Madison, Wisconsin 53792, United States
São Caetano do Sul, 09541-270, Brazil
Edmonton, Alberta T6G 2C8, Canada
Québec, Quebec G1J 1Z4, Canada
Wenzhou, Zhejiang 325000, China
Ramat Gan, Central District 5265601, Israel